{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:02:06Z","timestamp":1791248526315,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jaad.2016.03.024","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T18:17:08Z","timestamp":1463077028000},"page":"83-98.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":266,"title":["Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis"],"prefix":"10.1016","volume":"75","author":[{"given":"Peter C.M.","family":"van de Kerkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Papavassilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.03.024_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archdermatol.2012.370","article-title":"Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting","volume":"148","author":"Gelfand","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib5","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.03.024_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjd.12744","article-title":"Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09","volume":"170","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2016.03.024_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s11606-011-1698-5","article-title":"Psoriasis and\u00a0vascular disease-risk factors and outcomes: a systematic\u00a0review of the literature","volume":"26","author":"Patel","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib16","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jaad.2016.03.024_bib17","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12026-012-8276-8","article-title":"The potential of interleukin-17 to mediate hematopoietic response","volume":"52","author":"Krstic","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaad.2016.03.024_bib19","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1172\/JCI40891","article-title":"IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice","volume":"120","author":"Cho","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2016.03.024_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12026-011-8226-x","article-title":"IL-17 signaling in host defense against Candida albicans","volume":"50","author":"Gaffen","year":"2011","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaad.2016.03.024_bib21","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/eji.201242605","article-title":"Immunity to infection in IL-17-deficient mice and humans","volume":"42","author":"Cypowyj","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2016.03.024_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jaad.2016.03.024_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, non-inferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjd.13814","article-title":"Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)","volume":"173","author":"Tha\u00e7i","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib26","unstructured":"Clinicaltrials.gov. AIN457 regimen finding extension study in patients with moderate to severe psoriasis. NCT01132612. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01132612?term=NCT01132612&rank=1. Accessed June 15, 2015."},{"key":"10.1016\/j.jaad.2016.03.024_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1188\/06.CJON.164-166","article-title":"Care of patients with neutropenia","volume":"10","author":"Marrs","year":"2006","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.jaad.2016.03.024_bib28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib29","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.03.024_bib30","doi-asserted-by":"crossref","first-page":"AB189","DOI":"10.1016\/j.jaad.2014.01.783","article-title":"Serious infection events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study: current status of observations","volume":"70","author":"Kalb","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib31","first-page":"1137","article-title":"Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations","volume":"7","author":"Menter","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.03.024_bib34","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib35","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib37","first-page":"300","article-title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up","volume":"11","author":"Reich","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib39","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1001153","article-title":"IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans","volume":"185","author":"Kagami","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2016.03.024_bib40","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib41","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nri2742","article-title":"T(H)17 cells in tumour immunity and immunotherapy","volume":"10","author":"Zou","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2016.03.024_bib43","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Overview of the SEER program. Available at: http:\/\/seer.cancer.gov\/about\/overview.html. Accessed June 15, 2015."},{"key":"10.1016\/j.jaad.2016.03.024_bib44","first-page":"AB175","article-title":"Malignancy events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study: current status of observations","volume":"70","author":"Fiorentino","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib45","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.03.024_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/eurheartj\/ehs399","article-title":"Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown","volume":"34","author":"Liuzzo","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaad.2016.03.024_bib48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety\u00a0of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib49","first-page":"AB175","article-title":"Major adverse cardiovascular events in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study: current status of observations","volume":"70","author":"Gottlieb","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.03.024_bib50","unstructured":"Novartis. Data on file. Basel, Switzerland: Novartis."},{"key":"10.1016\/j.jaad.2016.03.024_bib51","doi-asserted-by":"crossref","first-page":"983902","DOI":"10.1155\/2013\/983902","article-title":"Correlations between psoriasis and inflammatory bowel diseases","volume":"2013","author":"Skroza","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaad.2016.03.024_bib52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O'Connor","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaad.2016.03.024_bib53","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2016.03.024_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaad.2016.03.024_bibS1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2016.03.024_bibS2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jaad.2016.03.024_bibS3","first-page":"857","article-title":"Confidence intervals for the mean of a Poisson distribution: a review","volume":"35","author":"Sahai","year":"1993","journal-title":"Biomed J"},{"key":"10.1016\/j.jaad.2016.03.024_bibS4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am J Epidemiol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221630007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221630007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:40:14Z","timestamp":1759272014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221630007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S019096221630007X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.03.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}